Akeso $9926.HK
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS67
PHASE 3 / 2-323
RECRUITING32
READOUTS ≤12 MONTHS26
READOUT SLIPPED >6 MO40%
Delay Index: of 40 active trials registered more than a year ago, 16 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Akeso on the live radar map → 📅 $9926.HK readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Ivonescimab (SMT112 or AK112) Injection NCT05184712 |
P3 | Active, not recruiting | Non-Squamous Non-small Cell Lung Cancer | 322 | 2023-03-10 (-10 mo) |
| AK104 NCT05319431 |
P2 | Active, not recruiting | Unresectable, Non-metastatic Hepatocellular Carcinoma | 60 | 2023-08-15 |
| AK112 NCT05499390 |
P3 | Active, not recruiting | Advanced Non-small-cell Lung Cancer | 398 | 2024-01-29 (-5 mo) |
| Cadonilimab NCT05960955 |
P2 | Recruiting | Resectable Gastric or Gastroesophageal Junction Adenocarcinoma | 90 | 2024-11-30 |
| AK112, Carboplatin, Paxlitaxel NCT05840016 |
P3 | Active, not recruiting | Advanced Squamous Non Small Cell Lung Cancer | 532 | 2025-02-28 (+2 mo) |
| AK104 NCT05859750 |
P2 | Recruiting | Pancreatic Cancer | 78 | 2025-06 |
| AK120 NCT06756126 |
P2 | Not yet recruiting | Atopic Dermatitis | 24 | 2025-06-30 |
| AK104 NCT05990127 |
P3 | Not yet recruiting | Locally Advanced or Metastatic NSCLC | 642 | 2025-08-05 |
| AK112 NCT05247684 |
P2 | Active, not recruiting | Resectable Non-small Cell Lung Cancer | 90 | 2025-08-18 (+24 mo) |
| AK117 NCT04900350 |
P1/2 | Active, not recruiting | Myelodysplastic Syndrome | 136 | 2025-09 (+28 mo) |
| AK117 NCT04980885 |
P1/2 | Active, not recruiting | Acute Myeloid Leukemia | 68 | 2025-09 (+26 mo) |
| AK104 NCT06371157 |
P3 | Recruiting | Hepatocellular Carcinoma | 469 | 2025-10-25 |
| AK109 NCT04982276 |
P1/2 | Recruiting | Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | 138 | 2025-12-30 (+43 mo) |
| AK104 NCT04982237 |
P3 | Active, not recruiting | Cervical Cancer | 445 | 2025-12-30 (+9 mo) |
| AK117 NCT06196203 |
P2 | Recruiting | Higher-risk Myelodysplastic Syndromes | 90 | 2026-01 |
| AK104 NCT05489289 |
P3 | Recruiting | Hepatocellular Carcinoma | 570 | 2026-01-28 (+12 mo) |
| Penpulimab NCT04974398 |
P3 | Active, not recruiting | Nasopharyngeal Carcinoma | 296 | 2026-02-23 (+32 mo) |
| AK117 NCT06387420 |
P1/2 | Not yet recruiting | ACUTE MYELOID LEUKEMIA; AML | 180 | 2026-04 |
| AK104-305 NCT05235516 |
P3 | Active, not recruiting | Locally Advanced Cervical Carcinoma | 636 | 2026-05 |
| AK127 in combination with AK112 NCT05951608 |
P1/2 | Active, not recruiting | Advanced Solid Tumors | 216 | 2026-05-01 (+10 mo) |
| AK104 NCT06560112 |
P2 | Recruiting | Recurrent Ovarian Cancer | 172 | 2026-05-01 |
| AK119 NCT05846867 |
P1/2 | Active, not recruiting | Colorectal Cancer | 170 | 2026-05-08 (+24 mo) |
| AK112 NCT05382442 |
P2 | Active, not recruiting | Metastatic Colorectal Cancer | 254 | 2026-05-15 (+43 mo) |
| AK112 NCT06530251 |
P1/2 | Recruiting | Hepatocellular Carcinoma | 280 | 2026-06 |
| AK112 NCT05904379 |
P1/2 | Active, not recruiting | Advanced Non-small-cell Lung Cancer | 233 | 2026-06-30 (+14 mo) |
| AK112 NCT04736823 |
P2 | Active, not recruiting | NSCLC | 265 | 2026-07 (+42 mo) |
| AK139 NCT07436234 |
P2 | Not yet recruiting | Seasonal Allergic Rhinitis | 111 | 2026-09-30 |
| AK112, Gemcitabine, Cisplatin NCT06591520 |
P3 | Active, not recruiting | Biliary Tract Cancer | 682 | 2026-10 (-9 mo) |
| Cadonilimab (AK104) NCT06617416 |
P3 | Recruiting | NSCLC (Non-small Cell Lung Cancer) | 560 | 2026-10-28 |
| cadonilimab NCT06341335 |
P3 | Recruiting | Gastric and Gastroesophageal Junction Adenocarcinoma | 506 | 2026-11 |
| AK104+lenvatinib NCT06984718 |
P2 | Not yet recruiting | HCC; Hepatocellular Carcinoma | 120 | 2026-11-30 |
| AK112 NCT06767527 |
P3 | Recruiting | Triple-Negative Breast Cancer (TNBC) | 416 | 2026-12 |
| AK129(dose 1) NCT06943820 |
P1/2 | Recruiting | Non-small Cell Lung Cancer Stage IIIB/IV; Head and Neck Squamous Cell Carcinoma (HNSCC) | 230 | 2026-12 |
| AK119 NCT05689853 |
P1/2 | Recruiting | Solid Tumor, Adult | 87 | 2026-12 (+30 mo) |
| AK139 NCT07436221 |
P2 | Not yet recruiting | Asthma | 160 | 2026-12-27 |
| AK117 NCT05227664 |
P2 | Active, not recruiting | Metastatic Triple-negative Breast Cancer; Locally Advanced Triple-negative Breast Cancer | 120 | 2026-12-30 (+47 mo) |
| AK112, Cadonilimab, nab-paclitaxel, gemcitabine NCT06646055 |
P1/2 | Active, not recruiting | Metastatic Pancreatic Ductal Adenocarcinoma | 110 | 2026-12-30 |
| AK112 NCT05229497 |
P1/2 | Active, not recruiting | Advanced Malignant Tumors | 154 | 2026-12-31 (+47 mo) |
| AK117 in combination with AK112 NCT06601335 |
P3 | Recruiting | Head and Neck Squamous Cell Carcinoma | 510 | 2027-01 |
| AK112 NCT06951503 |
P3 | Recruiting | Colorectal Adenocarcinoma | 560 | 2027-01-13 |
| VG2025 NCT07357220 |
P1/2 | Not yet recruiting | Colorectal Cancer With Hepatic Metastases | 72 | 2027-02-28 |
| AK109+AK104 NCT05142423 |
P1/2 | Recruiting | Advanced Solid Tumor | 198 | 2027-04 (+55 mo) |
| AK139 NCT07755371 |
P2 | Not yet recruiting | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 75 | 2027-04-30 |
| AK112 NCT06938321 |
P1/2 | Recruiting | Biliary Tract Cancer | 135 | 2027-05 |
| NSCLC NCT06928389 |
P3 | Recruiting | Non-Small Cell Lung Cancer | 536 | 2027-05 |
| TT-00420 (tinengotinib) NCT07052253 |
P2 | Recruiting | Hepatocellular Carcinoma (HCC) | 100 | 2027-05-10 |
| Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine NCT06953999 |
P3 | Recruiting | Pancreatic Cancer | 999 | 2027-05-14 |
| NCT06767540 NCT06767540 |
P3 | Not yet recruiting | Atopic Dermatitis | 198 | 2027-07-10 |
| AK139 NCT07883213 |
P2 | Not yet recruiting | Prurigo Nodularis (PN) | 132 | 2027-08 |
| AK112 NCT07114315 |
P2 | Recruiting | Pancreatic Cancer | 160 | 2027-08 |
| AK146D1 for injection NCT07669779 |
P2 | Recruiting | Advanced Non Small Cell Lung Cancer (NSCLC) | 348 | 2027-08-30 |
| AK146D1 for injection NCT07591090 |
P2 | Recruiting | Advanced Breast Cancer | 200 | 2027-09-01 |
| AK112 low dose NCT06686030 |
P2 | Recruiting | Platinum-sensitive Ovarian Cancer | 150 | 2027-10 |
| AK139 NCT07502222 |
P2 | Not yet recruiting | Moderate-to-Severe Atopic Dermatitis | 168 | 2027-11 |
| AK129 NCT06642792 |
P1/2 | Recruiting | Classic Hodgkin Lymphoma | 280 | 2027-11 |
| AK104(SC) NCT07449780 |
P3 | Not yet recruiting | Gastric / Gastroesophageal Junction Adenocarcinoma | 422 | 2027-11-17 |
| Ivonescimab NCT07245446 |
P2 | Recruiting | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | 180 | 2027-12 |
| AK138D1 NCT07560124 |
P1/2 | Not yet recruiting | Breast Cancer | 286 | 2028-06-06 |
| AK138D1 NCT07623356 |
P1/2 | Recruiting | Non-Small Cell Lung Cancer | 265 | 2028-06-18 |
| AK146D1 for injection NCT07636772 |
P2 | Not yet recruiting | Urothelial Carcinoma (UC) | 132 | 2028-08-24 |
| AGA TKI NSCLC NCT07158840 |
P2 | Not yet recruiting | Non-Small Cell Lung Cancer | 60 | 2028-09 |
| AK112-311 NCT07010263 |
P3 | Recruiting | Small Cell Lung Cancer | 560 | 2028-12-31 |
| AK139 NCT07875426 |
P2 | Not yet recruiting | Chronic Spontaneous Urticaria | 201 | 2029-01-08 |
| Cadonilimab NCT07023315 |
P3 | Recruiting | Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | 760 | 2029-07 |
| G/GEJ NCT07700979 |
P3 | Recruiting | Gastric / Gastroesophageal Junction Adenocarcinoma | 900 | 2029-08-18 |
| Cadonilimab (AK104) NCT07263919 |
P2 | Recruiting | Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | 90 | 2030-03 |
| Cadonilimab (AK104) NCT07412613 |
P3 | Recruiting | Resectable Colon Cancer; MSI-H/dMMR Colorectal Cancer | 386 | 2030-06-15 |